{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:24:04Z","timestamp":1769171044179,"version":"3.49.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009663","name":"University Health Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Effective treatment of respiratory infections continues to be a major challenge. In high doses (\u2265160 ppm), inhaled Nitric Oxide (iNO) has been shown to act as a broad-spectrum antimicrobial agent, including its efficacy <jats:italic>in vitro<\/jats:italic> for coronavirus family. However, the safety of prolonged <jats:italic>in vivo<\/jats:italic> implementation of high-dose iNO therapy has not been studied. Herein we aim to explore the feasibility and safety of delivering continuous high-dose iNO over an extended period of time using an <jats:italic>in vivo<\/jats:italic> animal model. Yorkshire pigs were randomized to one of the following two groups: group 1, standard ventilation; and group 2, standard ventilation + continuous iNO 160 ppm + methylene blue (MB) as intravenous bolus, whenever required, to maintain metHb &lt;6%. Both groups were ventilated continuously for 6 hours, then the animals were weaned from sedation, mechanical ventilation and followed for 3 days. During treatment, and on the third post-operative day, physiologic assessments were performed to monitor lung function and other significative markers were assessed for potential pulmonary or systemic injury. No significant change in lung function, or inflammatory markers were observed during the study period. Both gas exchange function, lung tissue cytokine analysis and histology were similar between treated and control animals. During treatment, levels of metHb were maintained &lt;6% by administration of MB, and NO<jats:sub>2<\/jats:sub> remained &lt;5 ppm. Additionally, considering extrapulmonary effects, no significant changes were observed in biochemistry markers. Our findings showed that high-dose iNO delivered continuously over 6 hours with adjuvant MB is clinically feasible and safe. These findings support the development of investigations of continuous high-dose iNO treatment of respiratory tract infections, including SARS-CoV-2.<\/jats:p>","DOI":"10.1371\/journal.pone.0258368","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T19:03:55Z","timestamp":1634151835000},"page":"e0258368","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["A novel pre-clinical strategy to deliver antimicrobial doses of inhaled nitric oxide"],"prefix":"10.1371","volume":"16","author":[{"given":"Vinicius S.","family":"Michaelsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela V. P.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edson","family":"Brambate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aadil","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aizhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layla","family":"Pires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3412-2298","authenticated-orcid":true,"given":"Mitsuaki","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anajara","family":"Gazzalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaf","family":"Keshavjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Del Sorbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-1938","authenticated-orcid":true,"given":"Marcelo","family":"Cypel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"pone.0258368.ref001","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni1001-907","article-title":"Nitric oxide and the immune response","volume":"2","author":"C Bogdan","year":"2001","journal-title":"Nat Immunol"},{"key":"pone.0258368.ref002","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1172\/JCI119473","article-title":"Perspectives series: host\/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. Mechanisms of nitric oxide-related antimicrobial activity","volume":"99","author":"FC Fang","year":"1997","journal-title":"J Clin Invest"},{"key":"pone.0258368.ref003","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jcf.2013.01.008","article-title":"Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia","volume":"12","author":"CC Miller","year":"2013","journal-title":"J Cyst Fibros"},{"key":"pone.0258368.ref004","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/00003246-200007000-00035","article-title":"Effects of inhaled nitric oxide in a rat model of Pseudomonas aeruginosa pneumonia","volume":"28","author":"KE Webert","year":"2000","journal-title":"Crit Care Med"},{"key":"pone.0258368.ref005","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.niox.2015.08.007","article-title":"Inhaled nitric oxide: Current clinical concepts","volume":"50","author":"P Bhatraju","year":"2015","journal-title":"Nitric Oxide\u2014Biol Chem"},{"key":"pone.0258368.ref006","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMra051884","article-title":"Inhaled Nitric Oxide Therapy in Adults","volume":"353","author":"MJD Griffiths","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0258368.ref007","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s15010-016-0879-x","article-title":"Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study","volume":"44","author":"C Deppisch","year":"2016","journal-title":"Infection"},{"key":"pone.0258368.ref008","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4161\/viru.20328","article-title":"The potential of nitric oxide releasing therapies as antimicrobial agents","volume":"3","author":"DO Schairer","year":"2012","journal-title":"Virulence"},{"key":"pone.0258368.ref009","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nrmicro1004","article-title":"Antimicrobial reactive oxygen and nitrogen species: Concepts and controversies","volume":"2","author":"FC Fang","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"pone.0258368.ref010","first-page":"1451","article-title":"The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the intensive care unit","volume":"50","author":"BB McMullin","year":"2005","journal-title":"Respir Care"},{"key":"pone.0258368.ref011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.niox.2005.01.006","article-title":"A direct nitric oxide gas delivery system for bacterial and mammalian cell cultures","volume":"12","author":"A Ghaffari","year":"2005","journal-title":"Nitric Oxide\u2014Biol Chem"},{"key":"pone.0258368.ref012","article-title":"Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N- acetylpenicillamine, a nitric oxide donor compound","author":"E Keyaerts","year":"2004","journal-title":"International Journal of Infectious Diseases"},{"key":"pone.0258368.ref013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.niox.2005.08.003","article-title":"Potential application of gaseous nitric oxide as a topical antimicrobial agent","volume":"14","author":"A Ghaffari","year":"2006","journal-title":"Nitric Oxide\u2014Biol Chem"},{"key":"pone.0258368.ref014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.niox.2008.08.002","article-title":"Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure","volume":"20","author":"C Miller","year":"2009","journal-title":"Nitric Oxide\u2014Biol Chem"},{"key":"pone.0258368.ref015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1099\/acmi.0.000154","article-title":"Antibacterial activity of high-dose nitric oxide against pulmonary Mycobacterium abscessus disease","volume":"2","author":"K Bogdanovski","year":"2020","journal-title":"Access Microbiol"},{"key":"pone.0258368.ref016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.niox.2020.08.004","article-title":"Ideation and assessment of a nitric oxide delivery system for spontaneously breathing subjects","volume":"104\u2013105","author":"S Gianni","year":"2020","journal-title":"Nitric Oxide\u2014Biol Chem"},{"key":"pone.0258368.ref017","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/AOG.0000000000004128","article-title":"High Concentrations of Nitric Oxide Inhalation Therapy in Pregnant Patients With Severe Coronavirus Disease 2019 (COVID-19)","volume":"136","author":"B Safaee Fakhr","year":"2020","journal-title":"Obstet Gynecol"},{"key":"pone.0258368.ref018","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcf.2019.05.002","article-title":"Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection","volume":"19","author":"L Bentur","year":"2020","journal-title":"J Cyst Fibros"},{"key":"pone.0258368.ref019","first-page":"2","article-title":"Inhaled nitric oxide therapy in acute bronchiolitis: A multicenter randomized clinical trial","volume":"10","author":"A Goldbart","year":"2020","journal-title":"Sci Rep"},{"key":"pone.0258368.ref020","first-page":"A2655","volume":"2020","author":"K Gardner","year":"2020","journal-title":"High-Dose Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia Multivorans"},{"key":"pone.0258368.ref021","article-title":"Safety of continuous 12-hour delivery of antimicrobial doses of inhaled nitric oxide during ex vivo lung perfusion","author":"VS Michaelsen","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"pone.0258368.ref022","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ilar.38.1.41","article-title":"The 1996 Guide for the Care and Use of Laboratory Animals","volume":"38","author":"JD Clark","year":"1997","journal-title":"ILAR J"},{"key":"pone.0258368.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-08261-z","article-title":"Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion","volume":"10","author":"M Galasso","year":"2019","journal-title":"Nat Commun"},{"key":"pone.0258368.ref024","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clinbiochem.2010.12.011","article-title":"A simple and inexpensive automated technique for measurement of serum nitrite\/nitrate","volume":"44","author":"E Tatsch","year":"2011","journal-title":"Clin Biochem"},{"key":"pone.0258368.ref025","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/bi00173a044","article-title":"Pre-steady-state kinetics of the microtubule-kinesin ATPase","volume":"33","author":"SP Gilbert","year":"1994","journal-title":"Biochemistry"},{"key":"pone.0258368.ref026","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.athoracsur.2016.10.062","article-title":"Sevoflurane Attenuates Ischemia-Reperfusion Injury in a Rat Lung Transplantation Model","volume":"103","author":"A Ohsumi","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"pone.0258368.ref027","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1439-0442.1996.tb00479.x","article-title":"Role of inosine in prevention of methaemoglobinaemia in the pig: in vitro studies","volume":"43","author":"P Sartorelli","journal-title":"Zentralbl Vet A"},{"key":"pone.0258368.ref028","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.biocel.2005.02.001","article-title":"Investigation of methaemoglobin reduction by extracellular NADH in mammalian erythrocytes","volume":"37","author":"EC Kennett","journal-title":"Int J Biochem Cell Biol"},{"key":"pone.0258368.ref029","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/08958379009145245","article-title":"Nitric oxide and nitrogen dioxide as inducers of acute pulmonary injury when inhaled at relatively high concentrations for brief periods","volume":"2","author":"DM Stavert","year":"1990","journal-title":"Inhal Toxicol"},{"key":"pone.0258368.ref030","unstructured":"National Institute for Occupational Safety and Health. Recommendations of occupational limits for nitrogen dioxide. In: September 28 [Internet]. 2011 [cited 15 Jul 2021]. https:\/\/www.cdc.gov\/niosh\/pel88\/10102-44.html."},{"key":"pone.0258368.ref031","first-page":"1","article-title":"Inhaled nitric oxide therapy and risk of renal dysfunction: A systematic review and meta-analysis of randomized trials","volume":"19","author":"SY Ruan","year":"2015","journal-title":"Crit Care"},{"key":"pone.0258368.ref032","first-page":"1","article-title":"Inhaled nitric oxide and the risk of renal dysfunction in patients with acute respiratory distress syndrome: A propensity-matched cohort study","volume":"20","author":"SY Ruan","year":"2016","journal-title":"Crit Care"},{"key":"pone.0258368.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-10-1","article-title":"Effects of inhaled nitric oxide on hemostasis in healthy adults treated with heparin: A randomized, controlled, blinded crossover study","volume":"10","author":"B Goldstein","year":"2012","journal-title":"Thromb J"},{"key":"pone.0258368.ref034","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1128\/IAI.71.5.2341-2349.2003","article-title":"Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis","volume":"71","author":"KEA Darling","year":"2003","journal-title":"Infect Immun"},{"key":"pone.0258368.ref035","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/INF.0000000000001780","article-title":"Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients","volume":"37","author":"K Yaacoby-Bianu","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"pone.0258368.ref036","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1128\/AAC.49.3.1209-1212.2005","article-title":"Inhaled nitric oxide treatment of patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"49","author":"R Long","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0258368.ref037","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ppul.23905","article-title":"Nitric oxide inhalations in bronchiolitis: A pilot, randomized, double-blinded, controlled trial","volume":"53","author":"A Tal","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"pone.0258368.ref038","article-title":"Inhaled nitric oxide in patients with the acute respiratory distress syndrome secondary to the 2009 influenza A (H1N1) infection in Canada","author":"DJ Funk","year":"2013","journal-title":"Canadian Journal of Anesthesia"},{"key":"pone.0258368.ref039","first-page":"153","volume":"163","author":"W Fang","year":"2021","journal-title":"The role of NO in COVID-19 and potential therapeutic strategies"},{"key":"pone.0258368.ref040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2009.09.007","article-title":"Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected","volume":"395","author":"S \u00c5kerstr\u00f6m","year":"2009","journal-title":"Virology"},{"key":"pone.0258368.ref041","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101734","article-title":"Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro","volume":"37","author":"D Akaberi","year":"2020","journal-title":"Redox Biol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0258368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T19:04:36Z","timestamp":1634151876000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0258368"}},"subtitle":[],"editor":[{"given":"Aleksandar R.","family":"Zivkovic","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0258368","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]}}}